FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/07/2026
Voltar para busca
Dado oficial do USPTO
S SENSIBLE BIOTECHNOLOGIES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
28/07/2026
Tipo de marca
Mista
Classes Nice
1, 5, 35, 42
Data de depósito
01/06/2023
Data de registro
28/04/2026
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/04/2026
Última transação
28/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
16
Localização do titular
SK
Examinador
FENNESSY, EDWARD JOHN
Unidade examinadora
L10
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "SENSIBLE BIOTECHNOLOGIES" appearing beneath a stylized uppercase letter "S" with two short parallel lines inside the curvature of the upper and lower portion of the letter, around which appears a circle composed of seventy-two dashed lines.
Titulares e representantes
Titulares
S. O. (pessoa física)
Representantes
Marek Krizka TRAMA LEGAL, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for use in industry; cell culture media for use in the biotechnological industry for scientific and research use; cell culture reagents for scientific and research use; biological preparation for use in cell cultures other than for medical or veterinary use; chemical for use in biotechnological manufacturing processes for use in molecular separation processes other than for medical or veterinary use; chemical for use in biotechnological product development for use in molecular separation processes other than for medical or veterinary use; cultures of microbiotic organismsother than for medical use; diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; cell culture media for microbiology for scientific and research purposes; biological preparations for use in science; biological preparations for use in industry; biological preparations for use in cell culturesother than for medical or veterinary purposes
Classe 5
Biotechnological preparations for use in cell cultures for medical purposes; cells for medical use; living cells for medical use
Classe 35
Retail store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies
Classe 42
Biotechnology testing of pharmaceutical preparations for gene therapypharmaceuticalschemicals and cell culture media; consulting services in the field of biotechnology; research and development in the pharmaceutical and biotechnology fields; writing of computer programs for biotechnological applications; development of measuring probes for biotechnological applications; research and development of new products in the field of biotechnology; designing equipment for the biotechnology industry; providing information on the subject of scientific research in the field of biochemistry and biotechnology; research in the field of cell engineering technology; cell culture services for scientific and research purposesfor others; analysis in the field of molecular biologymessenger RNA analysis to diagnose and treat diseases like COVID-19influenzaRSVZikaCMVHIVmelanomalung cancerpancreatic cancercystic fibrosispropionic acidemiamethylmalonic acidemiaFabry diseaseGaucher diseaseheart diseasemultiple sclerosisType 1 diabetesrheumatoid arthritisvarious allergies; research relating to molecular sciences; contract research services relating to molecular sciences; microbiological testing of cell culture mediaDNA and RNA to diagnose and treat diseases like COVID-19influenzaRSVZikaCMVHIVmelanomalung cancerpancreatic cancercystic fibrosispropionic acidemiamethylmalonic acidemiaFabry diseaseGaucher diseaseheart diseasemultiple sclerosisType 1 diabetesrheumatoid arthritisvarious allergies medical research; pharmaceutical research; biochemical analyses; biochemical research and development services in the field of messenger RNA to diagnose and treat diseases like COVID-19influenzaRSVZikaCMVHIVmelanomalung cancerpancreatic cancercystic fibrosispropionic acidemiamethylmalonic acidemiaFabry diseaseGaucher diseaseheart diseasemultiple sclerosisType 1 diabetesrheumatoid arthritisvarious allergies; laboratory analyses of materialsDNA and RNA materials to diagnose and treat diseases like COVID-19influenzaRSVZikaCMVHIVmelanomalung cancerpancreatic cancercystic fibrosispropionic acidemiamethylmalonic acidemiaFabry diseaseGaucher diseaseheart diseasemultiple sclerosisType 1 diabetesrheumatoid arthritisvarious allergies; biochemical research; biochemical analysis; biochemical research and development; biological laboratory research; chemical laboratory research; laboratory testing of materials; laboratory research in the field of chemistry; DNA testing for scientific research purposesDNA screeningdetermining DNA mutations; chemical laboratory services; biological research laboratory services; genetic engineering services in the field of genetic diseases; chemical analysis; scientific research in the field of genetics and genetic engineering; research and development in the field of microorganisms and cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/04/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
28/04/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/03/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/03/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/03/2026
PUBO
PUBLISHED FOR OPPOSITION
10/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2026
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
10/02/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/01/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
24/01/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
24/01/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
24/01/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
24/01/2026
RDX3
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
07/07/2025
RDX1
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
07/07/2025
RRDX
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
07/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/04/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/04/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
23/04/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/04/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
29/03/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/03/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/03/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
23/10/2024
GNFR
FINAL REFUSAL E-MAILED
23/10/2024
CNFR
FINAL REFUSAL WRITTEN
23/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/09/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/09/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/09/2024
RFNT
REFUSAL PROCESSED BY IB
08/04/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
19/03/2024
RFRR
REFUSAL PROCESSED BY MPU
18/03/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/02/2024
CNRT
NON-FINAL ACTION WRITTEN
24/02/2024
DOCK
ASSIGNED TO EXAMINER
23/02/2024
MAFR
APPLICATION FILING RECEIPT MAILED
24/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/10/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/10/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace S SENSIBLE BIOTECHNOLOGIES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.